<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505554</url>
  </required_header>
  <id_info>
    <org_study_id>CRU3</org_study_id>
    <nct_id>NCT03505554</nct_id>
  </id_info>
  <brief_title>A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma</brief_title>
  <acronym>CRU3</acronym>
  <official_title>A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define the objective response rates (ORR) of Lorlatinib in&#xD;
      subjects with ALK+ lymphomas resistant or refractory to ALK inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lorlatinib is a selective and potent tyrosine kinase inhibitor of ALK and ROS1 that&#xD;
      pre-clinically demonstrated dose-dependent inhibition of mutations that confer resistance to&#xD;
      other ALK inhibitors; it is also a brain-penetrant thus it might be active in patients with&#xD;
      CNS metastases.&#xD;
&#xD;
      Study Objectives Primary Define the objective response rates (ORR) of PF-06463922 in subjects&#xD;
      with ALK+ lymphomas resistant or refractory to ALK inhibitors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Define the Progression Free Survival (PFS) in subjects with ALK+ lymphomas resistant or&#xD;
           refractory to ALK inhibitors.&#xD;
&#xD;
        -  Define the overall survival (OS) in ALK+ lymphoma patients treated with Lorlatinib, that&#xD;
           are resistant or refractory to ALK inhibitors.&#xD;
&#xD;
        -  Determine the toxicity profile of Lorlatinib in ALK+ lymphoma patients resistant or&#xD;
           refractory to ALK inhibitors.&#xD;
&#xD;
        -  Determine the Quality of Life (QoL) in this population of patients using the EORTC-C30&#xD;
           Quality of Life questionnaire.&#xD;
&#xD;
        -  Study the mutational status of ALK pre/post Lorlatinib treatment through next-generation&#xD;
           sequencing (NGS).&#xD;
&#xD;
      Study design This is a phase 2 study open to 12 eligible patients with lymphoma with a&#xD;
      confirmed ALK rearrangement. All patients must have been pretreated with at least one line of&#xD;
      standard cytotoxic chemotherapy and at least one ALK inhibitor and they must have&#xD;
      demonstrated progression (regardless of initial response) or resistance on the last&#xD;
      treatment.&#xD;
&#xD;
      The study begins with a screening period to assess eligibility, up to and including 28 days&#xD;
      prior to the first dose of Lorlatinib. Treatment will continue until patient experiences&#xD;
      unacceptable toxicity or progressive disease (PD), starts a new anti-cancer therapy or dies.&#xD;
&#xD;
      The study will remain open until all patients have completed 3 years from the enrollment.&#xD;
&#xD;
      Study treatment Patients will receive an oral administration of Lorlatinib at a dose of 100mg&#xD;
      QD. In case of toxicity, it is possible to proceed to a dose reduction (75mg or 50mg QD) or a&#xD;
      temporary interruption of Lorlatinib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>up to 24 months</time_frame>
    <description>number, type and grade of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Use of EORTC-QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the mutational status of ALK pre/post Lorlatinib</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Mutational Analysis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Anaplastic Large Cell Lymphoma, ALK-Positive</condition>
  <arm_group>
    <arm_group_label>Lorlatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>100 mg QD</description>
    <arm_group_label>Lorlatinib</arm_group_label>
    <other_name>PF-06463922</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated Informed Consent approved by Local Ethical Committee before any&#xD;
             protocol-specific screening procedures.&#xD;
&#xD;
          2. ALK+ Lymphoma diagnosed by IHC or FISH.&#xD;
&#xD;
          3. Refractory disease or relapse after at least one prior chemotherapy regimen (typically&#xD;
             a minimum of 6 cycles of CHOP) and at least one ALK inhibitor; presence of measurable&#xD;
             disease by physical examination, CT or CT-PET scan.&#xD;
&#xD;
          4. Any prior antitumor medical treatment or major surgeries must have been completed at&#xD;
             least 14 days prior to initiation of study medication. This could not be respected if&#xD;
             there is clear evidence of disease progression, manifested as growing pain&#xD;
             attributable to the tumour, fever, growing tumour lesions, increasing LDH values.&#xD;
             Systemic anti-cancer therapy completed within a minimum of 5 half-lives of study&#xD;
             entry.&#xD;
&#xD;
          5. Able to take oral therapy.&#xD;
&#xD;
          6. Female or male, 18 years of age or older.&#xD;
&#xD;
          7. ECOG performance status 0-3.&#xD;
&#xD;
          8. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
             Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 2.5 x upper&#xD;
             limit of normal (ULN) or AST and ALT ≤ 5 x ULN if liver function abnormalities are due&#xD;
             to underlying malignancy Total serum bilirubin 1.5 x ULN (except patients with&#xD;
             documented Gilbert's syndrome Creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
          9. Adequate bone marrow function:&#xD;
&#xD;
             Absolute neutrophil count (ANC) ≥ 1000/µL Platelets ≥ 50.000/µL Hemoglobin ≥ 9.0 g/dL&#xD;
             The hematological values will not be considered in case of bone marrow involvement.&#xD;
&#xD;
         10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
         11. Female and male patients who are of childbearing potential must agree to use an&#xD;
             effective form of contraception (2 forms of contraception) with their partners&#xD;
             throughout participation in this study and for at least 90 days after the last dose of&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current treatment on another therapeutic clinical trial.&#xD;
&#xD;
          2. Clinically significant cardiovascular disease (that is, active or &lt;3 months prior to&#xD;
             enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable&#xD;
             angina, congestive heart failure (New York Heart Association Classification Class ≥&#xD;
             II)&#xD;
&#xD;
          3. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2: second-degree or third-degree AV&#xD;
             block (unless paced) or any AV block with PR &gt;220 msec, uncontrolled atrial&#xD;
             fibrillation of any grade, bradycardia defined as &lt;50 bpm (unless patient is otherwise&#xD;
             healthy such as long-distance runners, etc.), machine-read ECG with QTc &gt;470 msec, or&#xD;
             congenital long QT syndrome.&#xD;
&#xD;
          4. Pregnancy or breastfeeding.&#xD;
&#xD;
          5. Use of drugs or foods that are known strong or moderate CYP3A4 inhibitors, inducers&#xD;
             and substrates; drugs that are CYP2C9 substrates; drugs that are strong CYP2C19&#xD;
             inhibitors; drugs that are strong CYP2C8 inhibitors; and drugs that are P-gp&#xD;
             substrates.&#xD;
&#xD;
          6. Prior malignancy other than basal cell carcinoma , if original diagnosis happened in&#xD;
             the last 5 years.&#xD;
&#xD;
          7. Patients with predisposing characteristics for acute pancreatitis according to&#xD;
             investigator judgment (e.g. uncontrolled hyperglycemia, current gallstone disease,&#xD;
             alcoholism).&#xD;
&#xD;
          8. Hypertriglyceridemia ≥ grade 1.&#xD;
&#xD;
          9. Active and clinically significant bacterial, fungal, or viral infection including&#xD;
             hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or&#xD;
             acquired immunodeficiency syndrome (AIDS) related illness.&#xD;
&#xD;
         10. Other severe acute or chronic medical or psychiatric conditions, or laboratory&#xD;
             abnormalities that would impart, in the judgment of the investigator and/or sponsor,&#xD;
             excess risk associated with study participation or study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CARLO GAMBACORTI-PASSERINI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milano Bicocca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Mori, PhD</last_name>
    <phone>+390392339277</phone>
    <email>silvia.mori@unimib.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Baretta, SC</last_name>
    <phone>+390392339743</phone>
    <email>silvia.baretta1@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asst-Monza</name>
      <address>
        <city>Monza</city>
        <state>Italy/MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gambacorti-Passerini, MD</last_name>
      <phone>+390392339553</phone>
      <email>carlo.gambacorti@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Carlo Gambacorti-Passerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK</keyword>
  <keyword>relapsed</keyword>
  <keyword>lorlatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

